Felix Mahfoud

Nov 27, 2024 | radcliffecardiology.com | Ashley Park |Marc P. Bonaca |Sahil A. Parikh |Felix Mahfoud

AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD). Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).

Sep 18, 2024 | onlinelibrary.wiley.com | Gabriela M. Kuster |Birgit Assmus |Felix Mahfoud

Invited Editorial Myeloperoxidase: Reviving an old ally for immunomodulation in heart failure? Inhibition of myeloperoxidase to treat left ventricular dysfunction in non-ischaemic cardiomyopathy Simon Geissen, Simon Braumann, Joana Adler, Felix Sebastian Nettersheim, Dennis Mehrkens, Alexander Hof, Henning Guthoff, Philipp von Stein, Sven Witkowski, Norbert Gerdes, Frederik Tellkamp, Marcus Krüger, Lea Isermann, Aleksandra Trifunovic, Alexander C.

Feb 28, 2023 | jamanetwork.com | Ajay Kirtane |Felix Mahfoud |Roland E. Schmieder |Friedrich Alexander

[Skip to Navigation] Figure 1.  Design of the 3 Studies Included in the Pooled AnalysisThe studies included in the pooled analysis are A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN SOLO and TRIO) and A Study of the ReCor Medical Paradise System in Stage II Hypertension (RADIANCE II) trials.